This segment focuses on the research, development, and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. Lundbeck's R&D activities include drug discovery, preclinical studies, and clinical trials across various therapeutic areas, including depression, schizophrenia, Alzheimer's disease, and Parkinson's disease. The company utilizes advanced technologies and methodologies such as small molecule drug development and leverages partnerships to accelerate innovation. The patient impact is significant, as Lundbeck's treatments aim to improve the lives of individuals suffering from debilitating mental health and neurological conditions. Lundbeck's market positioning is strong, with a focus on specialty pharmaceuticals and a global presence. Future opportunities include expanding the product pipeline, exploring new therapeutic areas, and leveraging digital health technologies. Regulatory and clinical aspects are critical, with a focus on obtaining FDA and EMA approvals. Partnerships with companies like Verantos and Iambic Therapeutics support real-world evidence generation and AI-driven drug discovery.